02757—5032/
02758—5030
Dear Mr. Zapf:

Please refer to your supplemental new drug applications dated March 19, 2004, received March 22, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Avapro (irbesartan) Tablets, 75 mg, 150 mg and 300 mg (NDA 20-757) and Avalide (irbesartan/hydrochlorothiazide) Tablets, 75/12.5 mg, 150/12.5 mg and 300/12.5 mg (NDA 20-758).

These supplemental new drug applications provide for ___ as described in the March 18, 2004 amendment to DMF #______ for irbesartan drug substance.

We have completed our review of these supplemental applications and they are approved.

We remind you that you must comply with the reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any question, please call Edward Fromm, Regulatory Health Project Manager, at (301) 594-5332.

Sincerely,

[Signature]

Kasturi Srinivasachar, Ph.D.
Chemistry Team Leader, DNDC I for the Division of Cardio-Renal Drug Products (HFD-110)
DNDC I, Office of New Drug Chemistry Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

------------------
Kasturi Srinivasachar
7/21/04 05:21:53 PM
# DIVISION OF CARDIO-RENALE DRUG PRODUCTS

Review of Chemistry, Manufacturing, and Controls

<table>
<thead>
<tr>
<th>CHEMIST'S REVIEW</th>
<th>1. ORGANIZATION</th>
<th>2. NDA Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>HFD - 110</td>
<td></td>
<td>20-757</td>
</tr>
</tbody>
</table>

3. Name and Address of Applicant (City & State)
   Bristol-Myers Squibb Company
   P. O. Box 5400
   Princeton, NJ 08543-5400

4. Supplement(s)
   Number(s) Date(s)
   SCM-032 03/19/04

5. Drug Name
   Avapro

6. Nonproprietary Name
   Irbesartan

7. Amendments

8. Supplement Provides for:
   PRIOR APPROVAL SUPPLEMENT

9. Pharmacological Category
   Angiotensin II Receptor Antagonist/Hypertension

10. How Dispensed
    /x/ RX / / OTC

11. Related IND(s)/NDA(s)/DMF(s)
    NDA 20-758
    DMF

12. Dosage Form(s)
    Tablets

13. Potency(ies)
    75 mg, 150mg, and 300 mg.

14. Chemical Name
    2-Butyl-3-[(2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-1,3-diazaspiro[4.4]non-l-en-4-one.

15. Records/Reports
    Current
    /x/ Yes / / No
    Reviewed
    /x/ Yes / / No

16. Comments:
    As per Approved NDA or ANDA Guidance, dated November 1999, the process changes and supporting information described in this supplement are submitted in a Prior Approval Supplement.

17. Conclusions and Recommendations:
    The DMF # has been reviewed for the changes submitted in this supplement. The information provided in DMF is ADEQUATE to support the proposed C

    This supplement may be approved.

18. REVIEWER: Ramsharan D. Mittal
[] Page(s) Withheld

[✓] § 552(b)(4) Trade Secret / Confidential

[ ] § 552(b)(5) Deliberative Process

[ ] § 552(b)(5) Draft Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
------------------
Ramsharan Mittal
7/21/04 02:37:04 PM
CHEMIST

Kasturi Srinivasachar
7/21/04 05:11:28 PM
CHEMIST
NDA 20-757/S-032

PRIOR APPROVAL SUPPLEMENT

Sanofi-Synthelabo c/o Bristol-Myers Squibb Company
Attention: Mr. George Zapf
P.O. Box 5400
Princeton, NJ 08543-5400

Dear Mr. Zapf:

We have received your supplemental drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for the following:

Name of Drug Product: Avapro® (irbesartan) 75, 150, and 300 mg Tablets
NDA Number: 20-757
Supplement number: 032
Date of supplement: March 19, 2004
Date of receipt: March 22, 2004

This supplemental application proposes manufacturing process changes to the drug substance synthesis for irbesartan.

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, we will file the application on May 21, 2004, in accordance with 21 CFR 314.101(a). If the application is filed, the user fee goal date will be July 22, 2004.

All communications concerning this supplement should be addressed as follows:

U.S. Postal Service:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Attention: Division Document Room, 5002
5600 Fishers Lane
Rockville, Maryland 20857
Courier/Overnight Mail:
Food and Drug Administration
Center for Drug Evaluation and Research
Division of Cardio-Renal Drug Products, HFD-110
Attention: Division Document Room, 5002
1451 Rockville Pike
Rockville, Maryland 20852

If you have any questions, please call:

Mr. Edward Fromm
Regulatory Health Project Manager
(301) 594-5332

Sincerely,

{See appended electronic signature page}

Zelda McDonald
Chief, Project Management Staff
Division of Cardio-Renal Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Zelda McDonald
3/25/04 09:00:31 AM